Therapeutics

Tumor cells or endothelium can express some specific antigens that are not found in normal tissues or at a low level, which are usually difficult to detect or purify. The advantage of mRNA display peptides is that they can recognize and combine the corresponding antigens of tumors, and can screen any tumor cells or molecules. The screening of tumor antigen epitopes can further analyze the structure and function of antigens, and serve as a targeted delivery vehicle for anticancer drugs.

Structural and biochemical abnormalities of the brain or other nerves can lead to a series of neurological symptoms, including paralysis, muscle weakness, poor coordination and changes in consciousness level. At present, the medical community is trying to find new drugs to treat nervous system diseases. The appearance of mRNA display technology gives more possibilities for the discovery of new drugs in the nervous system, because small molecular drugs developed based on this technology are more likely to cross the blood-brain barrier than other biological macromolecules.

The prevalence of metabolic diseases, such as obesity, diabetes and fatty liver, is on the rise worldwide. At present, most drugs used to treat metabolic diseases contain small molecules, but due to the lack of clear binding pockets, it is difficult to target the interaction regions between proteins, and the long development cycle and high research and development costs limit its development. The protein or peptide mimics developed by mRNA display technology just solve this problem. Through the introduction of non-limiting structures, the targeting of PPI can be achieved, and the high-throughput library screening reduces the drug discovery cycle.

Immune system dysfunction can lead to autoimmune diseases, inflammatory diseases and cancer. When the immune system is not as active as normal, immune deficiency will occur, leading to repeated and life-threatening infections. At present, the drugs used to treat immune diseases mainly focus on immunosuppressants, which are used to control autoimmune diseases or inflammation in case of excessive tissue damage and prevent rejection after organ transplantation. In the process of new drug discovery, antibody fragments and small molecular peptides obtained through library screening have attracted wide attention due to their better targeting, low cytotoxicity and high oral bioavailability.